Bavarian Nordic is a biotechnology company focused on the research, development, and manufacturing of vaccines for infectious diseases. The company specializes in viral vector technology for antigen delivery and operates commercial-scale facilities for the production of live virus vaccines. Its portfolio includes travel vaccines and vaccines for public health preparedness, specifically targeting mpox and smallpox. Bavarian Nordic serves healthcare professionals, governments, and international organizations, with a commercial presence in key markets in Europe and the United States. The company maintains manufacturing facilities in the USA, Germany, and Switzerland, and employs a network of partners to expand capacity.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage bavarian-nordic.com
Sector Healthcare IR page bavarian-nordic.com/investor
Tags
vaccines, infectious diseases, viral vectors, live virus manufacturing, travel health, public health preparedness, mpox, smallpox
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 11.3%
ROI 10.7%
ROIC 14.0%
Profit margin 22.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 0.08%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 6.244B 5.716B 7.062B 3.151B 1.898B
Net profit 1.375B 987.97M 1.475B -347.38M -464.77M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • Bavarian Nordic donates 75,000 doses of MVA-BN® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile.
  • Building emergency reserves is an important milestone in global mpox preparedness, helping ensure timely and equitable access to vaccines.
  • This new initiative reflects Bavarian Nordic’s longstanding role as a trusted partner in global health security and its mission to protect people and communities, and save lives, through vaccines.

COPENHAGEN, Denmark, October 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it will strengthen global preparedness for mpox through a donation of 75,000 doses of its MVA-BN® vaccine to the newly established global mpox vaccine emergency stockpile, helping ensure that protection is available when and where it is needed. The creation of a new stockpile marks an important milestone in global mpox preparedness, helping to ensure timely and equitable access to vaccines and enabling effective outbreak response for communities around the world.

It is managed by the International Coordinating Group (ICG) on Vaccine Provision, a mechanism hosted by WHO that coordinates the allocation and deployment of emergency vaccine supplies to countries responding to outbreaks. Initial funding for the stockpile has been provided by Gavi, the Vaccine Alliance.

The donation complements a newly awarded contract to supply 150,000 doses to the stockpile. Bavarian Nordic’s contribution through both vaccine supply and donation reflects its longstanding commitment to global health security and its mission to protect people and communities, and save lives, through vaccines.

Hitesh Sahni, Senior Vice President, Public Preparedness at Bavarian Nordic, said: “Infectious diseases do not stop at borders, and communities need timely access to protection when outbreaks occur. The establishment of a global mpox vaccine emergency stockpile is an important milestone in strengthening preparedness for future outbreaks. Ensuring timely and equitable access to vaccines is critical to protecting populations and enabling an effective public health response. We are proud to embark on a new collaboration with ICG partners to build a more coordinated and resilient response to the recurring threat of mpox.” 

About the smallpox/mpox vaccine
MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), and the EU/EAA and United Kingdom (marketed as IMVANEX®). It was originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the US population, including immunocompromised individuals who are not recommended vaccination with replicating smallpox vaccines. MVA-BN is now indicated for use for individuals considered at risk for smallpox or mpox infection.

Bavarian Nordic has been a long-term supplier of the vaccine to national stockpiles. During the 2022-2024 mpox outbreaks, the Company supported governments and international organizations by expanding access to the vaccine to more than 70 countries worldwide.

In 2024, MVA-BN received WHO prequalification for the use of the vaccine by individuals aged 12 years and older, enabling procurement through the UN agency focusing on children’s health. More recently, the European Commission approved an extension of the vaccine's marketing authorization in the EU/EEA to include children aged 2 to under 12 years. This expanded indication further helps to address the unmet need for mpox vaccines among younger populations at increased risk of infection.

Bavarian Nordic is working with global partners on additional clinical studies to further expand the availability of MVA-BN for other vulnerable populations. In parallel, the Company is developing new manufacturing processes to allow for scaling of capacity to meet increased demand in the future.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and offer a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com  

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since the last announcement of transactions on October 19, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic: 

Number of shares Average purchase price, DKK Transaction value, DKK
Accumulated until October 19, 2026 824,213 218.83 180,366,576
October 19, 2026 20,823 236.63 4,927,336
October 20, 2026 14,132 239.60 3,386,089
October 21, 2026 40,000 244.01 9,760,284
October 22, 2026 35,000 243.05 8,506,894
October 23, 2026 30,045 243.77 7,323,955
Accumulated under the program 964,213 222.22 214,271,135

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com . 

Following these transactions, Bavarian Nordic holds a total of 4,522,804 treasury shares, corresponding to 5.71% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com  

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since the last announcement of transactions on October 12, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic: 

Number of shares Average purchase price, DKK Transaction value, DKK
Accumulated until October 12, 2026 656,327 213.95 140,419,107
October 12, 2026 9,000 239.48 2,155,288
October 13, 2026 47,000 239.26 11,245,168
October 14, 2026 31,075 236.11 7,337,202
October 15, 2026 30,925 235.92 7,295,857
October 16, 2026 49,886 238.82 11,913,954
Accumulated under the program 824,213 218.83 180,366,576

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com .

Following these transactions, Bavarian Nordic holds a total of 4,382,804 treasury shares, corresponding to 5.53% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com  

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Prompts

Bavarian Nordic (ticker BAVA), listed in Denmark.

ETFs Holding Bavarian Nordic

ETF Weight in ETF Shares Market value As of
DISV 0.19% 274,981 $ 9.762M Nov 12, 2026
AVDS 0.14% 14,220 $ 499.95K Nov 16, 2026
DFIS 0.09% 144,671 $ 5.136M Nov 12, 2026
DXIV 0.08% 5,336 $ 189.422K Nov 12, 2026
DFIC 0.03% 136,686 $ 4.852M Nov 12, 2026
DFSI 0.03% 8,825 $ 313.277K Nov 12, 2026
DFAX 0.02% 62,038 $ 2.202M Nov 12, 2026
DFAI 0.02% 92,113 $ 3.27M Nov 12, 2026
AVDE 0.01% 47,404 $ 1.667M Nov 16, 2026
AVDV 0.01% 56,171 $ 1.975M Nov 16, 2026
AVSD 0.01% 863 $ 30.342K Nov 16, 2026